| Literature DB >> 34295851 |
Mohammadreza Tabatabaei1, Gholamali Dorvashy2, Rasoul Soltani1, Shiva Samsamshariat2, Rokhsareh Meamar2, Ali Mohammad Sabzghabaee2.
Abstract
OBJECTIVE: Opioid abuse is widespread throughout the world. Aspiration pneumonia is a serious problem following opioid overdose and poisoning. This study aimed to evaluate the safety and effectiveness of antimicrobial management of opioid-overdose induced aspiration pneumonia in a referral poisoning management university hospital in Iran.Entities:
Keywords: Antibiotic regimen; aspiration pneumonia; opioid overdose; treatment
Year: 2021 PMID: 34295851 PMCID: PMC8259600 DOI: 10.4103/jrpp.JRPP_21_17
Source DB: PubMed Journal: J Res Pharm Pract ISSN: 2279-042X
Clinical characteristics of the study patients and their poisonings/overdose details
| Variable | |
|---|---|
| Underlying pulmonary disorder | 6 (11.3) |
| Underlying cardiovascular disorder | 3 (5.7) |
| Chief complaint upon admission | |
| Low level of consciousness | 44 (83) |
| Dyspnea | 5 (9.4) |
| Low level of consciousness + dyspnea | 2 (3.8) |
| Unreported | 2 (3.8) |
| Overdose type | |
| Intentional | 22 (41.5) |
| Unintentional | 11 (20.8) |
| Opioid type | |
| Methadone | 32 (60.4) |
| Opium | 9 (17) |
| Heroine | 5 (9.4) |
| Tramadol | 2 (3.8) |
| Buprenorphine | 1 (1.9) |
| Methadone + opium | 1 (1.9) |
| Unreported | 3 (5.7) |
| Concomitant drug use | |
| Yes | 18 (34) |
| No | 29 (54.7) |
| Unreported | 6 (11.3) |
| Time of referral from overdose (h) | |
| <6 | 7 (13.2) |
| 6–12 | 15 (28.3) |
| 13–18 | 7 (13.2) |
| 19–24 | 2 (3.8) |
| >24 | 2 (3.8) |
| Unreported | 20 (37.7) |
| Duration of hospitalization (days) | |
| 1–3 | 25 (47.2) |
| 4–7 | 16 (30.2) |
| 8–14 | 6 (11.3) |
| >14 | 6 (11.3) |
The type, characteristics, and the outcomes of treatment regimens in the study patients
| Variable | |
|---|---|
| Antibiotic regimen | |
| Ceftriaxone + clindamycin | 29 (54.7) |
| Ampicillin/sulbactam + meropenem | 1 (1.9) |
| Ampicillin/sulbactam + levofloxacin | 1 (1.9) |
| Ceftriaxone + levofloxacin | 2 (3.8) |
| Ceftazidime + clindamycin | 4 (7.6) |
| Levofloxacin | 3 (5.7) |
| Meropenem + levofloxacin + vancomycin | 1 (1.9) |
| Meropenem + clindamycin | 1 (1.9) |
| Meropenem + levofloxacin + linezolid | 1 (1.9) |
| Meropenem + linezolid | 1 (1.9) |
| Meropenem + teicoplanin | 1 (1.9) |
| Meropenem + vancomycin | 5 (9.5) |
| Metronidazole + ampicillin | 1 (1.9) |
| Piperacillin/tazobactam + levofloxacin | 1 (1.9) |
| Piperacillin/tazobactam + levofloxacin + teicoplanin | 1 (1.9) |
| The correctness of antibiotic regimen | 36 (67.9) |
| The correctness of antibiotics dose | 50 (94.3) |
| Treatment outcome | |
| Discharge with good state | 36 (67.9) |
| Discharge with fever | 3 (5.7) |
| Discharge with crackle and/or wheezing | 3 (5.7) |
| Discharge with intubation | 1 (1.9) |
| Discharge with bad state (personal consent) | 8 (15.1) |
| Death | 2 (3.8) |